| Literature DB >> 34292740 |
Dong-Gi Mun1, Patrick M Vanderboom1, Anil K Madugundu1,2,3,4, Kishore Garapati1,3,4, Sandip Chavan1, Jane A Peterson5, Mayank Saraswat1,3,4, Akhilesh Pandey1,2,6.
Abstract
Since the recent outbreak of COVID-19, there have been intense efforts to understand viral pathogenesis and host immune response to combat SARS-CoV-2. It has become evident that different host alterations can be identified in SARS-CoV-2 infection based on whether infected cells, animal models or clinical samples are studied. Although nasopharyngeal swabs are routinely collected for SARS-CoV-2 detection by RT-PCR testing, host alterations in the nasopharynx at the proteomic level have not been systematically investigated. Thus, we sought to characterize the host response through global proteome profiling of nasopharyngeal swab specimens. A mass spectrometer combining trapped ion mobility spectrometry (TIMS) and high-resolution QTOF mass spectrometer with parallel accumulation-serial fragmentation (PASEF) was deployed for unbiased proteome profiling. First, deep proteome profiling of pooled nasopharyngeal swab samples was performed in the PASEF enabled DDA mode, which identified 7723 proteins that were then used to generate a spectral library. This approach provided peptide level evidence of five missing proteins for which MS/MS spectrum and mobilograms were validated with synthetic peptides. Subsequently, quantitative proteomic profiling was carried out for 90 individual nasopharyngeal swab samples (45 positive and 45 negative) in DIA combined with PASEF, termed as diaPASEF mode, which resulted in a total of 5023 protein identifications. Of these, 577 proteins were found to be upregulated in SARS-CoV-2 positive samples. Functional analysis of these upregulated proteins revealed alterations in several biological processes including innate immune response, viral protein assembly, and exocytosis. To the best of our knowledge, this study is the first to deploy diaPASEF for quantitative proteomic profiling of clinical samples and shows the feasibility of adopting such an approach to understand mechanisms and pathways altered in diseases.Entities:
Keywords: COVID-19; diaPASEF; host response
Year: 2021 PMID: 34292740 PMCID: PMC8315246 DOI: 10.1021/acs.jproteome.1c00506
Source DB: PubMed Journal: J Proteome Res ISSN: 1535-3893 Impact factor: 4.466
Figure 1Performance evaluation and design of the study. (A) Bar charts of the number of protein groups from triplicates of PASEF-DDA and diaPASEF experiments. All LC-MS/MS experiments were acquired with the same parameters as described under the Methods section by injecting ∼1 μg of peptides from Jurkat cells. (B) Correlation of protein abundance from triplicate PASEF-DDA and diaPASEF analyses is shown. Quantitative values of proteins in PASEF-DDA and diaPASEF were obtained through MaxQuant and Spectronaut, respectively. (C) Overall workflow for DIA-based proteome profiling. The nasopharyngeal swab samples were processed and analyzed using the diaPASEF mode on timsTOF Pro mass spectrometer. The spectral library generated from PASEF-DDA data acquired from pooled samples was used for DIA interpretation through Spectronaut.
Figure 2Generation of a proteome catalog of the nasopharynx. (A) Comparison of nasopharynx proteomes with previous proteomics studies from NP swab or brush samples. (B) Cellular deduced subtypes of proteins identified in PASEF-DDA experiments. (C) Density distribution of precursor mass and ion mobility values of 102 392 precursors contained in the spectral library. (D) Distribution of iBAQ intensity of the identified proteins. The representative proteins known to be expressed in nasopharynx are marked as empty black circle. The missing proteins are marked as red circles. (E) MS/MS spectrum and mobilogram of experimental and synthetic peptide LEDTILSPTASR derived from the missing protein, CROCC2.
Figure 3Quantitative analysis using diaPASEF (A) Bar charts of the number of proteins acquired from diaPASEF experimental analysis of 45 SARS-CoV-2 positive and 45 negative samples. (B) Volcano plot describing protein expression changes between positive and negative samples. (C) Bar charts displaying type of molecules and subcellular localization for differentially expressed proteins. (D) Gene ontology analysis of upregulated proteins. Biological processes are shown ordered according to the false discovery rate from DAVID (FDR < 0.05). The size of circle denotes the number of proteins associated with each biological process.
Figure 4Functional analysis of upregulated proteins in SARS-CoV-2 positive subjects. (A) Representative canonical pathway elevated in positive samples. RIG-I-like receptors (RLRs) and Toll-like receptors (TLRs) mediated IFN-α/β production and downstream interferon signaling pathway are depicted. Box plots of selected proteins are shown. (B) Heatmap of 64 ISGs across 90 samples classified based on their function of RNA process, IFN regulators-antiviral effectors, inflammation, and metabolic regulation. (C) Protein–protein interactions of molecules related to Golgi organization, ER to Golgi vesicle-mediated transport and exocytosis. Box plots of proteins COG8, FOLR1, LMAN1 are shown. (D) Upregulated proteins that are known to interact with SARS-CoV-2.